Fluoroquinolones and the risk of aortic aneurysm or dissection: A population‐based propensity score‐matched German cohort study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025
DOI: 10.1002/phar.70020 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Julia Wicherski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Federal Institute for Drugs and Medical Devices (BfArM), Research Division, Pharmacoepidemiology, Bonn, Germany. Hauptthemen laut MEDLINE: Fluoroquinolones, Anti-Bacterial Agents, Aortic Dissection, Aortic Aneurysm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To investigate the risk of aortic aneurysm or dissection associated with fluoroquinolone (FQ) prescription compared to macrolides in German routine health care data in order to replicate the recent study ( Pharmacotherapy 2023;43:883) extending the results by contributing evidence for six additional broad‐spectrum antibiotic classes as active comparators.
Design
Cohort study in active comparator new user design comparing FQ with macrolides, tetracyclines, penicillins with extended spectrum, penicillins and beta‐lactamase inhibitor combinations, second‐ and third‐generation cephalosporins, sulfonamide and trimethoprim combinations, and lincosamides.
Setting
German statutory health insurance, the “Allgemeine Ortskrankenkasse” (AOK), January 2013 to December 2019.
Participants
Adults with at least one new prescription fill for FQ or active comparator antibiotics. New users were defined as individuals without antibiotic prescription fills, aortic aneurysm or dissection diagnoses, and hospitalization within 365 days prior to the cohort entry date. Users of FQ and active comparators were matched by nearest neighbor 1:1 propensity score matching. Main Outcome Measures Incident inpatient aortic aneurysm or dissection was observed within a 60‐day risk window. In sensitivity analyses, an extended risk window of 90 days was applied, and specific FQ agents, dosages, and diagnoses were stratified.
Results
FQ episodes were associated with an increased risk for aortic aneurysm or dissection compared to macrolides (aHR = 1.52 [1.33; 1.74]), which replicates the risk estimate of Garg et al. (aHR = 1.34 [1.17; 1.54]). This association was robust in a 90‐day risk window and for ciprofloxacin, levofloxacin, and moxifloxacin. Moxifloxacin comprised the greatest risk of aortic aneurysm or dissection compared to macrolides (aHR = 2.13 [1.64; 2.77]). Moreover, we observed similar associations when comparing FQ to tetracyclines, penicillins with extended spectrum, cephalosporins, and lincosamides (aHR = 1.86 [1.54; 2.24], aHR = 1.45 [1.28; 1.65], aHR = 1.23 [1.10; 1.37], and aHR = 1.73 [1.43; 2.11]), respectively.
Conclusion
In a German cohort study, FQ use was associated with a 52% increased risk for aortic aneurysm or dissection within 60 days compared with macrolide use. The risk of FQ‐associated aortic aneurysm or dissection compared to macrolides can be replicated in German routine health care data. Extending the analysis, we provided new insights that the effect size may depend on the chosen AC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal Institute for Drugs and Medical Devices (BfArM), Research Division, Pharmacoepidemiology, Bonn, Germany.
- German Centre for Neurodegenerative Diseases (DZNE), Pharmacoepidemiology in Neurodegenerative Disorders, Bonn, Germany.
- Research Institute of AOK (WIdO), Berlin, Germany.
- Division of Infectious Diseases, Department of Medicine II, University of Freiburg Faculty of Medicine and Medical Centre, Freiburg, Germany.
- Centre for Translational Medicine, University of Bonn, Bonn, Germany.
ORCID-Profile: Julia Wicherski, Jonas Peltner, Cornelia Becker, Katrin Schüssel, Gabriela Brückner, Helmut Schröder, Winfried V Kern, Britta Haenisch
Zitieren
APA
Wicherski, J., Peltner, J., Becker, C., Schüssel, K., Brückner, G., Schlotmann, A., Schröder, H., Kern, W. V., & Haenisch, B. (2025). Fluoroquinolones and the risk of aortic aneurysm or dissection: A population‐based propensity score‐matched German cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70020
Vancouver
Wicherski J, Peltner J, Becker C, Schüssel K, Brückner G, Schlotmann A, et al. Fluoroquinolones and the risk of aortic aneurysm or dissection: A population‐based propensity score‐matched German cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70020
BibTeX
@article{Wicherski2025,
author = {Wicherski, Julia and Peltner, Jonas and Becker, Cornelia and Schüssel, Katrin and Brückner, Gabriela and Schlotmann, Andreas and Schröder, Helmut and Kern, Winfried V and Haenisch, Britta},
title = {Fluoroquinolones and the risk of aortic aneurysm or dissection: A population‐based propensity score‐matched German cohort study},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
doi = {10.1002/phar.70020}
}
EUVIMED